ligands. Starting from a known adrenergic compound 1, structural modifications were made to obtain highly potent and selective TAAR1 ligands such as 12 (RO5166017), 18 (RO5256390), 36 (RO5203648), and 48 (RO5263397). These compounds exhibit drug-like physicochemical properties, have good oral bioavailability, and display in vivo activity in a variety of animal models relevant for psychiatric diseases
发现
2-氨基恶唑啉是
TAAR1
配体的新型结构类别。从已知的
肾上腺素化合物1开始,进行了结构修饰,以获得高效且选择性的
TAAR1
配体,例如12(RO5166017),18(RO5256390),36(RO5203648)和48(RO5263397)。这些化合物表现出类似药物的理化性质,具有良好的口服
生物利用度,并且在与精神疾病和成瘾有关的多种动物模型中显示出体内活性。